All Stories

  1. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
  2. First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence
  3. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
  4. Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis
  5. The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study
  6. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
  7. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory
  8. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study
  9. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
  10. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis
  11. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
  12. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
  13. Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers
  14. Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations
  15. Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure
  16. Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial
  17. Comparative efficacy of switching to natalizumab in active multiple sclerosis
  18. An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis
  19. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis
  20. Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention
  21. Effect of Natalizumab treatment on circulating CD4+ CD62L+ T-cells in Multiple Sclerosis patients
  22. The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
  23. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
  24. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
  25. The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals
  26. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
  27. Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments
  28. Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis
  29. Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study
  30. Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study
  31. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
  32. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
  33. Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
  34. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
  35. Improving patient–physician dialog: commentary on the results of the MS Choices survey
  36. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial
  37. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis
  38. Anxiety and depression in multiple sclerosis patients around diagnosis
  39. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
  40. Protein profiling of Guillain–Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry
  41. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
  42. Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery
  43. A computational platform for MALDI-TOF mass spectrometry data: Application to serum and plasma samples
  44. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
  45. Hand dystonia secondary to cervical demyelinating lesion
  46. Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®)
  47. Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period
  48. ‘Psychic Akinesia’ following Carbon Monoxide Poisoning
  49. Sleep Apneas, Convulsive Syncopes and Autonomic Impairment in Type I Arnold-Chiari Malformation
  50. Extrapyramidal Syndrome and Depression Induced by Flunarizine
  51. Cleavage of cystatin C is not associated with multiple sclerosis
  52. Quasims: eine weltweite Beobachtungsstudie der Interferon-Beta Präparate in der Therapie der schubförmigen Multiplen Sklerose
  53. Demyelinating motor Guillain-Barre syndrome following rubella
  54. Gender related cognitive impairment in MS
  55. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors
  56. The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy
  57. Acute motor conduction block neuropathy Another Guillain-Barre syndrome variant
  58. Apolipoprotein E genotype does not influence the progression of multiple sclerosis
  59. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?
  60. Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis
  61. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1b
  62. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy
  63. Steroid-responsive multifocal demyelinating neuropathy with central involvement
  64. Effect of rhTNF-α injection into rat sciatic nerve
  65. Introduction
  66. RANTES and MCP-1 secretion by mononuclear cells of patients with multiple sclerosis
  67. Interferon beta normalizes suppressor cell function in dysimmune neuropathies
  68. Letters to the editor
  69. Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder?
  70. Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder?
  71. Hand dystonia secondary to cervical demyelinating lesions: an electrophysiological study
  72. Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT
  73. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies
  74. Sclerosi multipla: Meccanismi patogenetici alla base della demielinizzazione
  75. Basal ganglia involvement in multiple sclerosis with alternating side paroxysmal dystonia
  76. Sympathetic skin response in hemispheric lesions
  77. Isolated Bovine Spinal Motoneurons Have Specific Ganglioside Antigens Recognized by Sera from Patients with Motor Neuron Disease and Motor Neuropathy
  78. Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons
  79. Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons
  80. Isolated failure of noradrenergic transmission in a case with orthostatic hypotension and hyperactivity of gastro-colic reflex
  81. Idiopathic recurring stupor: A case with possible involvement of the gamma-aminobutyric acid (GABA)ergic system
  82. Identification of glycoconjugates which are targets for anti-Gal(β1-3)GalNAc autoantibodies in spinal motor neurons
  83. F response in vascular and degenerative upper motor neuron lesions
  84. Diurnal variability in cranial dystonia
  85. Physiological hypnic myoclonus
  86. Fasciculations during wakefulness and sleep
  88. Fatal Familial Insomnia and Dysautonomia with Selective Degeneration of Thalamic Nuclei
  89. Effect of oxygen radicals and hyperoxia on rat heart ornithine decarboxylase activity